Go to content

News

Filters

Changing any of the form inputs will cause the content to refresh with the filtered results.

Skip filters

Why Does the Future of Genetic Medicines Rely on LNP Targeting Strategies? Read What Experts Have to Say

Active targeting via site-specific ligand attachment, including DARPin conjugation, enables high-affinity cell recognition and has shown ~90% mRNA expression in human CD8⁺ T cells, supporting in-vivo CAR-T concepts.

Read about Why Does the Future of Genetic Medicines Rely on LNP Targeting Strategies? Read What Experts Have to Say

Optimising potency and delivery: the new frontier of LNP in mRNA cancer vaccines

Optimising potency and delivery: the new frontier of LNP in mRNA cancer vaccines.

Read about Optimising potency and delivery: the new frontier of LNP in mRNA cancer vaccines

Biotech Firms Cement a Longstanding Collaboration via Strategic Investment

Read about Biotech Firms Cement a Longstanding Collaboration via Strategic Investment

Acuitas Therapeutics Buys Majority Stake In RNA Technologies & Therapeutics

Read about Acuitas Therapeutics Buys Majority Stake In RNA Technologies & Therapeutics

Acuitas Takes Majority stake in Montreal-based RNA Construct Manufacturer

Acuitas Therapeutics shelled out an undisclosed sum to acquire a majority stake in Montreal-based and privately held RNA Technologies & Therapeutics.

Read about Acuitas Takes Majority stake in Montreal-based RNA Construct Manufacturer

Acuitas Therapeutics: Interview With President & CEO Dr. Thomas Madden About The Biotech Company

Read about Acuitas Therapeutics: Interview With President & CEO Dr. Thomas Madden About The Biotech Company

A Year of Firsts: Personalized Gene Editing Comes of Age

Read about A Year of Firsts: Personalized Gene Editing Comes of Age

Seven Biopharma Trends to Watch in 2026

Read about Seven Biopharma Trends to Watch in 2026

A Look Ahead: Predictions for the Life Sciences in 2026

Read about A Look Ahead: Predictions for the Life Sciences in 2026

GEN Editors Reflect on Six of the Biggest Stories of the Year

Alex Philippidis

Read about GEN Editors Reflect on Six of the Biggest Stories of the Year

New and notable treatments from 2025

Read about New and notable treatments from 2025

From One Patient to Many: How Baby KJ is Ushering in a New Era in CRISPR Medicine

Read about From One Patient to Many: How Baby KJ is Ushering in a New Era in CRISPR Medicine